#United States #Eagan #Sonex Health #UltraGuideCTR #Carpal Tunnel

Sonex Health Achieves Enrollment Target in Groundbreaking Study

Sonex Health, Inc. has reached an important milestone in its ongoing commitment to enhancing patient care by successfully enrolling over 1,300 participants in the MISSION study, the largest multi-arm clinical research initiative in the United States focused on carpal tunnel syndrome (CTS) treatments. This extensive research effort aims to improve overall patient experiences through informed surgical choices.

The MISSION clinical registry evaluates three different surgical techniques for treating CTS: ultrasound-guided carpal tunnel release (UGCTR) using Sonex Health's UltraGuideCTR™, endoscopic carpal tunnel release (ECTR), and open carpal tunnel release (OCTR).

The study's implementation is spearheaded by The Institute of Advanced Ultrasound Guided Procedures, co-founded by Dr. Darryl Barnes and Dr. Jay Smith. This institute is dedicated not only to innovation in ultrasound technology but also to setting benchmarks in clinical research and professional education in musculoskeletal ultrasound.

Innovative Techniques for Treatment

The groundbreaking MISSION study is designed to gather real-world data about the various methods utilized in carpal tunnel surgery, analyzing outcomes such as symptom relief, functional restoration, pain levels, and patient satisfaction.

Dr. Bob Paulson, President and CEO of Sonex Health, emphasizes the company’s mission: “We aim to empower physicians with solutions that not only enhance patient safety but also expedite recovery times. By pioneering these innovative therapies, we strive to reduce the invasiveness of procedures while lowering the overall cost of care.”

Enrolling a Diverse Patient Population

The impressive feat of enrolling over 1,300 patients within just 18 months showcases the urgency and significance of this study. Patients participating in the MISSION registry will provide feedback through online follow-up surveys at multiple intervals—ranging from one week to two years post-surgery—enabling the researchers to meticulously track recovery journeys.

The data collected will contribute to a series of peer-reviewed articles expected to be published in 2026, which will expand upon existing literature and enhance the understanding of various treatment approaches. Prior studies have already demonstrated significant effects of ultrasound-guided techniques, with 16 publications already available on this topic.

“High-quality clinical research is crucial in providing insights into patient-reported outcomes across different treatment modalities,” explains Dr. Victor Marwin, the lead investigator for the MISSION study. “Such extensive research allows healthcare providers and patients alike to make informed decisions regarding the best surgical options available.”

The Road Ahead

Looking to the future, Sonex Health is committed to continuing its trailblazing path in ultrasound-guided surgery, holding 51 patents and maintaining an extensive pipeline of innovative products. With ongoing educational initiatives, the institute plans to train more physicians in advanced techniques, further enhancing the landscape of orthopedic care.

As research progresses, the implications of the MISSION study extend beyond the walls of medical institutions—promoting greater accessibility and understanding of treatment options among patients and payers alike.

Sonex Health’s dedication to revolutionizing care through their technology is evident in their collaborative efforts with The Institute of Advanced Ultrasound Guided Procedures. This partnership exemplifies a commitment to improving not only surgical outcomes but also the entire patient journey, ensuring that healthcare remains responsive and personalized.

For additional information about the MISSION clinical registry and the ongoing innovations at Sonex Health, interested parties can visit Sonex Health.